StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)

Close on Nov 18, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

UroGen Pharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$158.92M. For fiscal 2025 it was -$162.44M. The highest annual figure on record is $4.19M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$162.44M–
FY2024Dec 31, 2024-$96.77M–
FY2023Dec 31, 2023-$76.38M–
FY2022Dec 31, 2022-$87.56M–
FY2021Dec 31, 2021-$84.89M–
FY2020Dec 31, 2020-$105.89M–
FY2019Dec 31, 2019-$71.02M–
FY2018Dec 31, 2018-$37.33M–
FY2017Dec 31, 2017-$9.57M-328.4%
FY2016Dec 31, 2016$4.19M–
FY2015Dec 31, 2015-$7.18M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$33.01M–
Q1 FY2026Mar 31, 2026-$45.32M–
Q4 FY2025Dec 31, 2025-$38.33M–
Q3 FY2025Sep 30, 2025-$42.27M–
Q2 FY2025Jun 30, 2025-$39.83M–
Q1 FY2025Mar 31, 2025-$42.02M–
Q4 FY2024Dec 31, 2024-$13.62M–
Q3 FY2024Sep 30, 2024-$27.66M–
Q2 FY2024Jun 30, 2024-$23.75M–
Q1 FY2024Mar 31, 2024-$31.74M–
Q4 FY2023Dec 31, 2023-$13.00M–
Q3 FY2023Sep 30, 2023-$17.30M–
Q2 FY2023Jun 30, 2023-$20.27M–
Q1 FY2023Mar 31, 2023-$25.81M–
Q4 FY2022Dec 31, 2022-$21.75M–
Q3 FY2022Sep 30, 2022-$17.61M–
Q2 FY2022Jun 30, 2022-$24.20M–
Q1 FY2022Mar 31, 2022-$24.00M–
Q4 FY2021Dec 31, 2021-$20.07M–
Q3 FY2021Sep 30, 2021-$18.48M–
Q2 FY2021Jun 30, 2021-$18.95M–
Q1 FY2021Mar 31, 2021-$27.40M–
Q4 FY2020Dec 31, 2020-$21.24M–
Q3 FY2020Sep 30, 2020-$25.08M–
Q2 FY2020Jun 30, 2020-$23.93M–
Q1 FY2020Mar 31, 2020-$35.64M–
Q4 FY2019Dec 31, 2019-$26.00M–
Q3 FY2019Sep 30, 2019-$12.53M–
Q2 FY2019Jun 30, 2019-$14.56M–
Q1 FY2019Mar 31, 2019-$17.93M–
Q4 FY2018Dec 31, 2018-$10.28M–
Q3 FY2018Sep 30, 2018-$9.28M-457.3%
Q2 FY2018Jun 30, 2018-$8.15M–
Q1 FY2018Mar 31, 2018-$9.62M–
Q4 FY2017Dec 31, 2017-$5.96M–
Q3 FY2017Sep 30, 2017$2.60M–
Q2 FY2017Jun 30, 2017-$3.46M–
Q1 FY2017Mar 31, 2017-$2.75M–

More UroGen Pharma figures

See a number that looks wrong?